ALX Oncology Holdings Inc. reports company news around a clinical-stage oncology pipeline led by evorpacept, an investigational CD47 inhibitor designed to address a cancer immune-evasion signal. Updates commonly cover clinical data presentations, biomarker analyses involving CD47 expression, and studies of evorpacept combinations in HER2-positive cancers, including breast and gastric cancer settings.
The company also reports development activity for ALX2004, an EGFR-targeted antibody-drug conjugate for EGFR-expressing solid tumors. Other recurring updates include quarterly financial results, research and development spending, cash runway commentary, registered offerings of common stock and pre-funded warrants, leadership appointments, investor conference participation, and Nasdaq inducement equity grants.
ALX Oncology (NASDAQ: ALXO) appointed Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight brings more than 30 years of biopharma and oncology experience across clinical development, regulatory affairs, and operations.
The company said his hire aims to strengthen development capabilities ahead of expected catalysts for evorpacept and ALX2004 over the next 12–18 months and to support late‑stage development and commercialization readiness.
ALX Oncology (Nasdaq: ALXO) reported Q4 and full‑year 2025 results and a corporate update on Feb 27, 2026. Key clinical advances include biomarker‑driven evidence that CD47 overexpression predicts evorpacept activity, ASPEN‑09‑Breast enrollment and ALX2004 dose‑escalation progress. Financially, the company completed a $150.0M registered offering (net $140.4M) and held $48.3M cash at year‑end, extending runway through 1H 2028.
Upcoming milestones: full biomarker poster at ESMO Breast (May 7, 2026), ALX2004 safety data in 2H 2026, and ASPEN‑09 topline for 80 patients mid‑2027.
ALX Oncology (Nasdaq: ALXO) announced participation in three investor events in Q1 2026: Wells Fargo Executive Biotech Summit (one-on-one meetings, Feb 24-25, 2026, Lake Tahoe, CA), TD Cowen 46th Annual Health Care Conference (presentation, Mar 3, 2026, 9:10 AM EST, Boston, MA; webcast available), and UBS Biotech Summit (one-on-one meetings, Mar 10, 2026, Miami, FL).
The TD Cowen webcast will be accessible via the Investors section at www.alxoncology.com and replayed for up to 90 days.
ALX Oncology (Nasdaq: ALXO) will report fourth quarter and full year 2025 financial results and provide a business update on Friday, February 27, 2026 before market open.
The company will host a teleconference and live audio webcast at 5:30am PT / 8:30am ET; a replay and corporate presentation will be archived on the investor section of the company website.
ALX Oncology (Nasdaq: ALXO) priced an underwritten offering to sell 76,979,112 shares of common stock and pre-funded warrants for 18,574,120 shares at $1.57 per share (pre-funded warrant price $1.569).
The offering is expected to close on or about Feb 2, 2026, with gross proceeds of approximately $150 million before expenses. Net proceeds are to fund continued clinical development of evorpacept and the ALX2004 program and for general corporate purposes.
ALX Oncology (Nasdaq: ALXO) reported exploratory Phase 1b/2 data showing CD47 expression predicts response to investigational CD47 inhibitor evorpacept combined with Ziihera (zanidatamab-hrii) in HER2-positive metastatic breast cancer. In nine centrally confirmed HER2-positive patients the combination produced a 56% confirmed objective response rate and median PFS of 7.4 months. The full biomarker analysis has been submitted for presentation at an upcoming scientific congress and reinforces prior ASPEN-06 gastric cancer findings linking CD47 expression to benefit.
ALX Oncology (Nasdaq: ALXO) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation and fireside chat on January 15, 2026 at 12:00 p.m. PT. A live webcast will be available via the Investors section of ALX Oncology’s website under Events and Presentations. A replay of the webcast will be archived and available for up to 90 days after the fireside chat.
ALX Oncology (Nasdaq: ALXO) announced clinical progress for two investigational therapies. The company dosed the first patient in the Phase 2 ASPEN-09-Breast trial of evorpacept combined with trastuzumab and physician’s choice chemotherapy in HER2-positive metastatic breast cancer post-ENHERTU; an interim analysis is anticipated in Q3 2026. The Phase 1 study of EGFR-targeted ADC ALX2004 advanced to a third dose cohort at 4 mg/kg after no dose-limiting toxicities in the first two cohorts; an initial safety update is expected in 1H 2026.
The ASPEN-09 trial will enroll ~80 patients and use CD47 expression and HER2 ctDNA as biomarkers; primary endpoint is overall response rate (ORR).
ALX Oncology (NASDAQ: ALXO) reported positive Phase 2 investigator‑sponsored data for evorpacept combined with rituximab and lenalidomide (R2) in untreated indolent B‑cell non‑Hodgkin lymphoma presented at ASH 2025.
In 24 frontline patients (14 follicular, 10 marginal zone), the regimen met its primary objective: 92% complete response (CR), 8% partial response, 100% overall response rate, one‑year PFS 91% and one‑year OS 100%. Investigators reported the combination was well tolerated; MRD evaluation and longer follow‑up were noted as next steps.
ALX Oncology (Nasdaq: ALXO) announced management will present at two investor conferences: a fireside chat at the Jefferies Global Healthcare Conference in London on Nov 19, 2025 at 11:30 AM GMT / 6:30 AM EST, and a fireside chat at the Piper Sandler 37th Annual Global Healthcare Conference in New York on Dec 3, 2025 at 9:30 AM EST.
Both events will be webcast; live links are available in the Investors > Events and Presentations section at www.alxoncology.com. Replays of each webcast will be archived for up to 90 days after the presentation dates.